Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia Academic Article uri icon

Overview

MeSH Major

  • Adenine Nucleotides
  • Arabinonucleosides
  • Leukemia, Myeloid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

abstract

  • Current treatments for relapsed/refractory leukemias are unable to achieve extended remissions in most patients even with multiagent chemotherapy. Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia. We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine. The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively.

publication date

  • September 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/MPH.0b013e318142b94b

PubMed ID

  • 17805046

Additional Document Info

start page

  • 656

end page

  • 8

volume

  • 29

number

  • 9